Current Cancer Drug Targets · 2023 · 102 citations · 51 references
MedicineOncologyPharmacologyCarcinogenesisGynecologic OncologyMolecular OncologyAngiogenesisAngiogenesis In CancerOvarian CancerTargeted Cancer TherapyTargeted TherapyTyrosine Kinase InhibitorsAntibodiesParp InhibitionPi3k InhibitorsPoly Adp-ribose Polymerase InhibitorsPoly(adp-ribose) Polymerase InhibitionPoly(adp-ribose) Polymerase InhibitorsVascular Endothelial Growth FactorVascular Endothelial Growth Factor Inhibitors
Ovarian cancer has become the largest cause of gynaecological cancer-related mortality. It is typically diagnosed at a late stage and has no effective screening strategy. Ovarian cancer is a highly heterogeneous disease that can be subdivided into several molecular subsets. As a result of a greater understanding of molecular pathways involved in carcinogenesis and tumor growth, targeted agents have been approved or are in several stages of development. Poly(ADP-ribose) polymerase (PARP) inhibitors and the anti-vascular endothelial growth factor (VEGF)-A antibodies are two types of approved and most effective targeted drugs for ovarian cancer at present. With the success of bevacizumab, tyrosine kinase inhibitors which could target alternate angiogenic pathways are being studied. Furthermore, many treatments targeting the PI3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathways, are being developed or are already in clinical studies. MicroRNAs have also become novel biomarkers for the therapy and clinical diagnosis of ovarian cancer. This manuscript reviews the molecular, preclinical and clinical evidence supporting the targeting of growth-dependent pathways in ovarian cancer and assesses current data related to targeted treatments beyond PARP inhibitors.
51
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Lin Zhang, José R. Conejo-García, Dionyssios Katsaros et al. · New England Journal of Medicine · 2003 · 3.4K citations · Full text
Medicine, Immunology, Oncology +17
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine · 2011 · 2.4K citations · Full text
Medicine, Gynecology, Oncology +11
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy Perren, Ann Marie Swart, Jacobus Pfisterer et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +11
MicroRNA Signatures in Human Ovarian Cancer
Marilena V. Iorio, Rosa Visone, Gianpiero Di Leva et al. · Cancer Research · 2007 · 1.4K citations · Full text